IDI2-AS1: A Potential Drug Target and Biomarker for Various Diseases

Target Name: IDI2-AS1

NCBI ID: G55853

IDI2-AS1

Other Name(s): IDI2-AS | C10orf110 | IDI2 antisense RNA 1 | HT009 | IDI2-AS1 variant 1

IDI2-AS1: A Potential Drug Target and Biomarker for Various Diseases

The IDI2-AS1 protein is a potential drug target (also known as IDI2-AS1) and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. IDI2-AS1 is a 21-kDa protein that is expressed in various tissues and cells in the body. It is a key regulator of the insulin-like growth factor (IGF) signaling pathway, which is involved in cell growth, differentiation, and survival. In this article, we will discuss the IDI2-AS1 protein, its function, potential drug targets, and its potential as a biomarker for various diseases.

Function of IDI2-AS1

IDI2-AS1 is a member of the insulin-like growth factor (IGF) signaling pathway, which is a critical pathway that regulates cell growth, differentiation, and survival. The IGF pathway is composed of several proteins that play a crucial role in regulating the growth and differentiation of cells. IDI2-AS1 is one of the proteins that is involved in the regulation of the IGF pathway.

IDI2-AS1 is a 21-kDa protein that is expressed in various tissues and cells in the body. It is highly conserved and has a similar structure to other proteins that are involved in the IGF pathway. IDI2-AS1 has four known functions, including:

1. Regulation of IGF-1 signaling pathway: IDI2-AS1 plays a key role in regulating the IGF-1 signaling pathway. It binds to the IGF-1 receptor and inhibits the downstream signaling of the pathway. This helps to ensure that cells do not grow too rapidly and can maintain proper cell size and shape.

2. Regulation of cell proliferation: IDI2-AS1 has been shown to regulate cell proliferation. It has been shown to inhibit the inhibition of cell proliferation by various signaling pathways, including the TGF-β pathway.

3. Role in cancer progression: IDI2-AS1 has been shown to contribute to the progression of cancer. It has been shown to promote the growth and survival of various cancer cell types, including breast, ovarian, and prostate cancers.

4. Potential drug target: IDI2-AS1 is a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its functions make it an attractive target for small molecule inhibitors, including anti-inflammatory drugs and kinase inhibitors.

Potential Drug Targets

IDI2-AS1 is a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its functions make it an attractive target for small molecule inhibitors, including anti-inflammatory drugs and kinase inhibitors.

Anti-inflammatory drugs: IDI2-AS1 has been shown to contribute to the development and progression of various inflammatory diseases, including cancer and neurodegenerative diseases. It has been shown to promote the growth and survival of cancer cells and to contribute to the development of neurodegenerative diseases. Therefore, anti-inflammatory drugs, such as corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs), may be effective in inhibiting the activity of IDI2-AS1 and may be a promising approach for the treatment of various diseases.

Kinase inhibitors: IDI2-AS1 has been shown to play a role in the regulation of cell signaling pathways, including the IGF-1 signaling pathway. Therefore, kinase inhibitors, which are drugs that inhibit the activity of protein kinases, may be effective in inhibiting the activity of IDI2-AS1 and may be a promising approach for the treatment of various diseases.

Biomarker Potential

IDI2-AS1 has the potential to serve as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression and function have been

Protein Name: IDI2 Antisense RNA 1

The "IDI2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IDI2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets